ZFPM2-AS1, a Novel LncRNA, Attenuates the P53 Pathway and Promotes Gastric Carcinogenesis by Stabilizing MIF

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2018 Jul 10

PMID 29985481

Citations 57

Authors

Fanyang Kong

Xuan Deng

Xiangyu Kong

Yiqi Du

Lei Li

Huiyun Zhu

Yuxin Wang

Dacheng Xie

Shivani Guha

Zhaoshen Li

Ming Guan

Keping Xie

Affiliations

Soon will be listed here.

Abstract

Long non-coding RNAs (lncRNAs) are implicated to be involved in the pathogenesis of many cancers. Herein we report on our discovery of a novel lncRNA, ZFPM2 antisense RNA 1 (ZFPM2-AS1), and its critical role in gastric carcinogenesis. ZFPM2-AS1 expression in gastric cancer specimens was analyzed using Gene Expression Omnibus data set and validated in 73 paired gastric tumor and normal adjacent gastric tissue specimens using qRT-PCR. The effect of ZFPM2-AS1 expression on proliferation and apoptosis in gastric cancer cells was assessed by altering its expression in vitro and in vivo. Mechanistic investigation was carried out using cell and molecular biological approaches. ZFPM2-AS1 expression was higher in gastric tumors than in normal gastric tissue. Also, increased ZFPM2-AS1 expression in gastric cancer specimens was associated with tumor size, depth of tumor invasion, differentiation grade, and TNM stage. High ZFPM2-AS1 expression predicted markedly reduced overall and disease-free survival in gastric cancer patients. Functional experiments demonstrated that ZFPM2-AS1 expression promoted proliferation and suppressed apoptosis of gastric cancer cells in vitro and promoted tumor growth in vivo. This effect is associated with attenuated nuclear translocation of p53. Mechanistic experiments demonstrated that tumor-activated ZFPM2-AS1 could bind to and protect the degradation of macrophage migration inhibitory factor (MIF), a potent destabilizer of p53. Knockdown of MIF expression diminished ZFPM2-AS1's impact on p53 expression in gastric cancer cells. Our findings demonstrated that ZFPM2-AS1 regulates gastric cancer progression and revealed a novel ZFPM2-AS1/MIF/p53 signaling axis, shedding light on the molecular mechanisms underlying the tumorigenicity of certain malignant gastric cells.

Citing Articles

Integrative analyses of bulk and single-cell RNA-seq reveals the correlation between SPP1 macrophages and resistance to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.

Geng Z, Li F, Yang Z, Li B, Xu Y, Wu B Cancer Immunol Immunother. 2024; 73(12):257.

PMID: 39367943 PMC: 11455823. DOI: 10.1007/s00262-024-03848-6.

Unraveling the influence of LncRNA in gastric cancer pathogenesis: a comprehensive review focus on signaling pathways interplay.

Elimam H, Mageed S, Hatawsh A, Moussa R, Radwan A, Elfar N Med Oncol. 2024; 41(9):218.

PMID: 39103705 DOI: 10.1007/s12032-024-02455-w.

LncRNA ZFPM2-AS1 promotes phyllodes tumor progression by binding to CDC42 and inhibiting STAT1 activation.

He S, Huang G, Lei R, Jia R, He Z, Chen J Acta Pharm Sin B. 2024; 14(7):2942-2958.

PMID: 39027255 PMC: 11252458. DOI: 10.1016/j.apsb.2024.04.023.

Circulating long noncoding RNA, Zfpm2-As1, and XIST based on medical data analysis are potential plasma biomarkers for gastric cancer diagnosis.

Liang H, Li H, Xia N, Chen J, Gao L, Liu H Technol Health Care. 2024; 32(6):4919-4928.

PMID: 38820035 PMC: 11612959. DOI: 10.3233/THC-232033.

Macrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (DDT): Pathways to Tumorigenesis and Therapeutic Opportunities.

Valdez C, Sanchez-Zuno G, Bucala R, Tran T Int J Mol Sci. 2024; 25(9).

PMID: 38732068 PMC: 11084905. DOI: 10.3390/ijms25094849.

References

Ulitsky I, Bartel D . lincRNAs: genomics, evolution, and mechanisms. Cell. 2013; 154(1):26-46. PMC: 3924787. DOI: 10.1016/j.cell.2013.06.020. View

Fu M, Zou C, Pan L, Liang W, Qian H, Xu W . Long noncoding RNAs in digestive system cancers: Functional roles, molecular mechanisms, and clinical implications (Review). Oncol Rep. 2016; 36(3):1207-18. DOI: 10.3892/or.2016.4929. View

Villegas V, Zaphiropoulos P . Neighboring gene regulation by antisense long non-coding RNAs. Int J Mol Sci. 2015; 16(2):3251-66. PMC: 4346893. DOI: 10.3390/ijms16023251. View

Wang K, Chang H . Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43(6):904-14. PMC: 3199020. DOI: 10.1016/j.molcel.2011.08.018. View

Lopez-Saez J, de la Torre C, Pincheira J, Gimenez-Martin G . Cell proliferation and cancer. Histol Histopathol. 1998; 13(4):1197-214. DOI: 10.14670/HH-13.1197. View

Lin Y, Ueda J, Kikuchi S, Totsuka Y, Wei W, Qiao Y . Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol. 2011; 17(39):4421-8. PMC: 3218157. DOI: 10.3748/wjg.v17.i39.4421. View

Sun B, Nishihira J, Suzuki M, Fukushima N, Ishibashi T, Kondo M . Induction of macrophage migration inhibitory factor by lysophosphatidic acid: relevance to tumor growth and angiogenesis. Int J Mol Med. 2003; 12(4):633-41. View

Schulz R, Streller F, Scheel A, Ruschoff J, Reinert M, Dobbelstein M . HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer. Cell Death Dis. 2014; 5:e980. PMC: 4040658. DOI: 10.1038/cddis.2013.508. View

Salminen A, Kaarniranta K . Control of p53 and NF-κB signaling by WIP1 and MIF: role in cellular senescence and organismal aging. Cell Signal. 2010; 23(5):747-52. DOI: 10.1016/j.cellsig.2010.10.012. View

10.

Shi X, Sun M, Wu Y, Yao Y, Liu H, Wu G . Post-transcriptional regulation of long noncoding RNAs in cancer. Tumour Biol. 2015; 36(2):503-13. DOI: 10.1007/s13277-015-3106-y. View

11.

Zhang C, Zhu K, Ma X . Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2. Cancer Lett. 2017; 396:66-75. DOI: 10.1016/j.canlet.2017.03.018. View

12.

Mitchell R, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J . Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci U S A. 2002; 99(1):345-50. PMC: 117563. DOI: 10.1073/pnas.012511599. View

13.

Jung H, Seong H, Ha H . Direct interaction between NM23-H1 and macrophage migration inhibitory factor (MIF) is critical for alleviation of MIF-mediated suppression of p53 activity. J Biol Chem. 2008; 283(47):32669-79. DOI: 10.1074/jbc.M806225200. View

14.

Tan P, Yeoh K . Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma. Gastroenterology. 2015; 149(5):1153-1162.e3. DOI: 10.1053/j.gastro.2015.05.059. View

15.

Yang S, He P, Wang J, Schetter A, Tang W, Funamizu N . A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. Cancer Res. 2016; 76(13):3838-50. PMC: 4930741. DOI: 10.1158/0008-5472.CAN-15-2841. View

16.

Schmitt A, Chang H . Long Noncoding RNAs in Cancer Pathways. Cancer Cell. 2016; 29(4):452-463. PMC: 4831138. DOI: 10.1016/j.ccell.2016.03.010. View

17.

Schulz R, Marchenko N, Holembowski L, Fingerle-Rowson G, Pesic M, Zender L . Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J Exp Med. 2012; 209(2):275-89. PMC: 3280870. DOI: 10.1084/jem.20111117. View

18.

Brock S, Rendon B, Xin D, Yaddanapudi K, Mitchell R . MIF family members cooperatively inhibit p53 expression and activity. PLoS One. 2014; 9(6):e99795. PMC: 4059697. DOI: 10.1371/journal.pone.0099795. View

19.

Wight M, Werner A . The functions of natural antisense transcripts. Essays Biochem. 2013; 54:91-101. PMC: 4284957. DOI: 10.1042/bse0540091. View

20.

Imazeki F, Omata M, Nose H, OHTO M, Isono K . p53 gene mutations in gastric and esophageal cancers. Gastroenterology. 1992; 103(3):892-6. DOI: 10.1016/0016-5085(92)90022-q. View